Pharmactive promotes black garlic extract that beneficial to cardiovascular
Recently, the biotechnology company Pharmactive Biotech launched the ABG10 + extract of Chen black garlic, which was conducted by the Autonomous University of Madrid under the leadership of Dr. Sara Amor and was published in the Journal of Nutrition.
ABG10 + is the first batch of black garlic extracts using high-performance Liquid Chromatography technology containing standard high-concentration S-allylcysteine (SAC) and produced using the company's proprietary aging process.
In this 16-week study, rats in each group were fed standard diets or diets containing large amounts of fat and sucrose. Beginning at the eighth week, half of the rats in the high-fat diet ingested Pharmactive Chen Black Garlic Extract. It was found that compared with the untreated rats, the average calorie intake, body weight, triglycerides , Low-density lipoprotein (LDL) Cholesterol, INSULIN and leptin serum concentrations decreased, HLD cholesterol was higher. In addition, Chen Hei garlic extract reduced fat weight and reduced vasoconstriction caused by obesity in rats on high-fat diet.
The researchers said that further research is needed to assess the differences in the bioavailability of supplements between rats and humans.
Looking for chemical products? Let suppliers reach out to you!
2026-07-03
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Semaglutide initiates Phase III clinical trial of NASH in China
-
Aging of arteries is an important feature of cardiovascular diseases
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Merck and Eisai Halt Late-Stage Trial for Liver Cancer Therapy
-
U.S. Health Chief Says No Evidence Linking Tylenol to Autism
-
Lilly Eyes Fast-Track Approval for Oral Weight-Loss Drug in U.S.
-
Strides Pharma Reports Strong Q2 as Net Profit Surges 82%
Recommend Reading
-
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
-
India Strengthens Drug Approval Oversight with Expanded CDSCO Powers
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
Significant Supply Increase, Acrylonitrile Market Weak and Fluctuating
-
Expected Minor Fluctuations in Lithium Carbonate Prices in October
-
Maleic Anhydride Continues to Decline in September, But May See an Upward Trend in October
-
Post-holiday, China's propylene oxide prices slightly increase
-
Field Low Prices Decrease, Acrylic Acid Market Remains Firm